Global healthcare company Abbott on Monday announced the launch of a dual-chamber leadless pacemaker system, which will help the heart beat properly without wires or surgical pockets used in traditional pacemakers. Pacemakers help keep the heart beating at a healthy pace, especially in the case of bradycardia, a condition where the heart beats too slowly. In a statement, Abbott said its implant-to-implant device technology enables wireless communication and synchronisation between two leadless pacemakers, which are smaller than an AAA battery. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. "As leadless pacing technology has evolved, we've built upon our AVEIR VR single-chamber platform to expand the benefits of leadless pacing to far more people and provide additional treatment options to patients," said Ajay Singh Chauhan, General Manager for Abbott's cardiac rhyt

Number of FII/FPI investors increased from 208 to 215 in Jun 2025 qtr.

Global Health Ltd.

04 Oct 2025

1362.90

1.00%

Company Update

Global Health Ltd - 543654 - Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunil Sachdeva

pdf

Global Health Ltd.

26 Sep 2025

1362.90

1.00%

Astronauts with diabetes may soon travel safely to space, finds study

Business Standard

Astronauts with diabetes may soon be able to undertake space missions safely, a study conducted during Shubhanshu Shukla's travel to the International Space Station has found. The Suite Ride experiment, conducted by UAE-based healthcare firm Burjeel Holdings during the Axiom-4 mission, found that everyday diabetes tools used by millions on Earth can be used comprehensively to provide end-to-end diabetes monitoring from space to ground and back to space. "This historic advancement opens the door to future astronauts with diabetes and provides new solutions in remote healthcare," a statement from Burjeel Holdings said. The results of the study were announced at the Burjeel Institute for Global Health, New York, in the presence of Shamsheer Vayalil, founder of Burjeel Holdings and Tejpaul Bhatia, CEO, Axiom Space. As per the research results, continuous glucose monitors (CGMs), a wearable medical device tracking blood sugar levels in real time, and insulin pens can operate reliably in